The HER2 targeting ADC trastuzumab emtansine, trastuzumab deruxtecan, Trop-2 targeting ADC sacituzumab govitecan, Brentuximab vedotin and enfortumab vedotin has shown great efficacy as neoadjuvant chemotherapy in breast cancer, lymphoma, and invasive urothelial cancer22–27. This evidence concerns the gene TACSTD2 and breast carcinoma.